Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.7K
5.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

R233H mutation in patients with tyrosine hydroxylase deficiency and corresponding phenotypes: a study of four cases and literature review.

Journal of integrative neuroscience·2022
Same author

Bioactivity-guided isolation of polyacetylenes with inhibitory activity against NO production in LPS-activated RAW264.7 macrophages from the rhizomes of Atractylodes macrocephala.

Journal of ethnopharmacology·2013
Same author

[Biotransformation by human intestinal flora and absorption-transportation characteristic in a model of Caco-2 cell monolayer of d-corydaline and tetrahydropalmatine].

Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica·2013
Same author

Clinical characteristics and genetic profiles of 44 patients with severe combined immunodeficiency (SCID): report from Shanghai, China (2004-2011).

Journal of clinical immunology·2012
Same author

Four new dammarane-type triterpene saponins from the stems and leaves of Panax ginseng and their cytotoxicity on HL-60 cells.

Planta medica·2011
Same author

Distribution and clinical features of primary immunodeficiency diseases in Chinese children (2004-2009).

Journal of clinical immunology·2011

Related Experiment Video

Updated: Apr 19, 2026

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.7K

Dehydroxymethylepoxyquinomicin selectively ablates T-CAEBV cells.

Hui Zhang1, Wen-Tao Yang1, Zhao Wang1

  • 1Department of Pediatrics, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200092, China.

Frontiers in Bioscience (Landmark Edition)
|January 2, 2015
PubMed
Summary

Activated nuclear factor kappa B (NF-kB) plays a role in Chronic Active Epstein-Barr Virus (CAEBV) infection. A novel inhibitor, DHMEQ, shows promise in selectively inducing apoptosis in CAEBV-infected cells.

More Related Videos

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers
10:49

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers

Published on: September 26, 2019

6.1K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.4K

Related Experiment Videos

Last Updated: Apr 19, 2026

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.7K
A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers
10:49

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers

Published on: September 26, 2019

6.1K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.4K

Area of Science:

  • Oncology
  • Virology
  • Immunology

Background:

  • Chronic Active Epstein-Barr Virus (CAEBV) infection is a lymphoproliferative disorder with high morbidity and mortality.
  • CAEBV infection can lead to malignant transformation of infected cells, necessitating novel therapeutic strategies.
  • Current therapeutic options for CAEBV are limited, highlighting the need for effective treatments to prevent disease progression.

Purpose of the Study:

  • To investigate the role of activated nuclear factor kappa B (NF-kB) in T-cell type CAEBV infection.
  • To identify potential therapeutic targets for preventing CAEBV-mediated malignant transformation.
  • To evaluate the efficacy of dehydroxymethylepoxyquinomicin (DHMEQ) as a novel therapeutic agent for CAEBV.

Main Methods:

  • Microarray analysis to identify key molecular pathways involved in CAEBV.
  • Luciferase reporter assays to assess NF-kB activation in CAEBV-infected cells.
  • In vitro cellular and molecular experiments to evaluate the effects of DHMEQ on CAEBV-infected SNT-16 cells.

Main Results:

  • Activated NF-kB was identified as a potential key player in T-cell type CAEBV infection.
  • Dehydroxymethylepoxyquinomicin (DHMEQ) selectively induced apoptosis in CAEBV-infected SNT-16 cells.
  • DHMEQ-induced apoptosis was mediated by NF-kB inhibition and oxidative stress generation.

Conclusions:

  • Activated NF-kB represents a promising therapeutic target for CAEBV.
  • DHMEQ demonstrates selective targeting of CAEBV-infected cells, suggesting its potential as a novel therapeutic candidate.
  • DHMEQ may offer a new treatment strategy to control CAEBV progression and prevent malignant transformation.